P. Senter

Nature Biotechnology · 2003–2023

A researcher in the Science corpus: 6 papers; trusts 0 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Who trusts P. Senter overall

  1. S. Panowski
  2. P. Carter

Papers from P. Senter's perspective

Ordered by how strongly the researchers P. Senter trusts endorse each paper. Same corpus, a different order for every researcher.

  1. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. (Blood)
  2. The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular… (Journal of Biological Chemistry)
  3. Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* (Journal of Biological Chemistry)
  4. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. (Journal of Clinical Oncology)
  5. Improving the efficacy of antibody-based cancer therapies (Nature Reviews. Cancer)
  6. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. (Cancer Research)
  7. Present and Future
  8. Arming antibodies: prospects and challenges for immunoconjugates (Nature Biotechnology)
  9. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. (Clinical Cancer Research)
  10. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (Cancer Research)

Their papers